BRAF and neoplasm: B-RAF presents in 77.7% of all patients included in our study, which is a subtype of RAF kinase, as an activation of the MAPK pathway, which plays an essential role in regulating tumor growth and proliferation [37], indicating a higher risk of recurrence and a worse prognosis [5].